Literature DB >> 9504627

Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma.

Y J Wen1, M Ling, S H Lim.   

Abstract

Multiple myeloma idiotypic protein is clone-specific and therefore represents an ideal tumour antigen for immune targeting. In this study we determined whether a synthetic peptide corresponding to the autologous idiotypic VH CDR3 sequence could elicit peptide-specific immune responses in a patient with IgA myeloma. Not unlike B-cell lymphoma, the immune repertoire of the patient contained T cells capable of mounting proliferative and cytotoxic responses to antigen-presenting cells loaded with the CDR3 peptide. Furthermore, the T cells were also able to secrete interferon-gamma upon peptide rechallenge. Antigen recognition by peptide-primed T cells was MHC dependent and could be blocked by antibodies to both monomorphic MHC class I and class II molecules. These results therefore indicate the presence of T-cell epitopes on the VH CDR3 sequence. In addition, CDR3 peptide-primed T cells were also able to mount similar immune responses when rechallenged with the intact IgA idiotypic protein, suggesting that functional T-cell epitopes had been derived from the CDR3 sequence of the idiotypic protein. Our results therefore provide a new perspective to the immunogenicity of the idiotypic protein in myeloma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9504627     DOI: 10.1046/j.1365-2141.1998.00592.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Authors:  Jinsheng Weng; Soung-Chul Cha; Satoko Matsueda; Gheath Alatrash; Michael S Popescu; Qing Yi; Jeffrey J Molldrem; Michael Wang; Sattva S Neelapu; Larry W Kwak
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

2.  Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Authors:  Michael Hundemer; Stefanie Schmidt; Maud Condomines; Alaviana Lupu; Dirk Hose; Marion Moos; Friedrich Cremer; Christian Kleist; Peter Terness; Sebastian Belle; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Olaf Christensen
Journal:  Exp Hematol       Date:  2006-04       Impact factor: 3.084

Review 3.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

4.  Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.

Authors:  Sivasubramanian Baskar; Carol B Kobrin; Larry W Kwak
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

5.  Construction and characterization of single-chain variable fragment antibody library derived from germline rearranged immunoglobulin variable genes.

Authors:  Man Cheng; Shirley Y W Chan; Qi Zhao; Elaine Y M Chan; Shannon W N Au; Susanna S T Lee; Wing-Tai Cheung
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

6.  Expression of testicular genes in haematological malignancies.

Authors:  S H Lim; S Austin; E Owen-Jones; L Robinson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.